• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC

New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
Classification Namestimulator, autonomic nerve, implanted for epilepsy
Generic Namestimulator, autonomic nerve, implanted for epilepsy
Cyberonics, Inc.
100 cyberonics blvd.
houston, TX 77058-2017
PMA NumberP970003
Supplement NumberS045
Date Received10/24/2002
Decision Date02/28/2003
Product Code
LYJ[ Registered Establishments with LYJ ]
Advisory Committee Neurology
Supplement Typereal-time process
Supplement Reason labeling change - indications/instructions/shelf life/tradename
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval for the following labeling change to the individualization of treatment section of the model 100/101 and 102 physician's manuals "preclinical study, teratogenic effects; there are no adequate and well-controlled studies of vns in pregnant women. Reproduction studies have been performed using female rabbits stimulated with the commercially available vns therapy system at stimulation dose settings similar to those used for humans. These animal studies have revealed no evidence of impaired fertility or harm to the fetus due to vns therapy. Because animal reproduction studies are not always predictive of human response and animal studies cannot address developmental abnormalities, vns should be used during pregnancy only if clearly needed. Although the operating ranges of the vns therapy system and fetal monitors are dissimilar and no interaction would be expected, testing has not been performed. Therefore, the potential may exist for interaction between the vns therapy system and fetal monitoring systems. ".